Amgen’s stock hits a 52-week high, signaling institutional interest in the biotech giant. With solid revenue growth in Q4 and full year 2025, AMGN is up 13.7% over three months. The breakout at a reasonable forward P/E of 15.6x indicates potential for higher valuations driven by earnings power and catalysts.

AMGN’s earnings profile with EPS of $22.33 this year and $22.92 next year reflects steady growth. Wall Street’s price targets show improving sentiment, with RBC, Goldman Sachs, and Cantor Fitzgerald raising targets. AMGN’s breakout charts suggest the market underestimates its durability and revenue growth potential, presenting a bullish opportunity.

Amgen’s 52-week high is backed by fundamentals, not hype. With 10% revenue growth, a forward P/E of 15.6x, and strong momentum, AMGN offers quality, scale, and catalysts without a tech-style premium. The breakout confirms AMGN’s leadership position in large-cap healthcare, presenting a compelling investment opportunity for investors seeking growth and stability.

Read more at Nasdaq: Zacks Investment Ideas feature highlights: Amgen, Apple and Microsoft